Myomo, Inc. (NYSEAMERICAN:MYO) Sees Significant Decline in Short Interest

Myomo, Inc. (NYSEAMERICAN:MYO) was the recipient of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 1,124,493 shares, a drop of 39.1% from the July 30th total of 1,847,205 shares. Currently, 3.2% of the shares of the company are short sold. Based on an average daily trading volume, of 889,567 shares, the short-interest ratio is presently 1.3 days.

Insiders Place Their Bets

In related news, insider Harry Kovelman sold 17,250 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $1.73, for a total transaction of $29,842.50. Following the transaction, the insider directly owned 105,983 shares of the company’s stock, valued at approximately $183,350.59. This trade represents a 14.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas F. Kirk acquired 40,002 shares of the company’s stock in a transaction on Friday, June 5th. The stock was acquired at an average price of $1.27 per share, with a total value of $50,802.54. Following the purchase, the director directly owned 693,865 shares in the company, valued at approximately $881,208.55. This represents a 6.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.14% of the stock is currently owned by company insiders.

Institutional Trading of Myomo

Several institutional investors and hedge funds have recently modified their holdings of MYO. Engineers Gate Manager LP grew its position in Myomo by 62.8% in the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock valued at $65,000 after acquiring an additional 11,614 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Myomo by 93.6% in the third quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock worth $27,000 after acquiring an additional 14,705 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Myomo in the first quarter worth about $75,000. Invesco Ltd. acquired a new stake in shares of Myomo in the 2nd quarter valued at approximately $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Myomo during the 2nd quarter valued at approximately $38,000. 44.99% of the stock is currently owned by institutional investors.

Myomo Price Performance

Shares of NYSEAMERICAN:MYO traded down $0.04 during midday trading on Wednesday, hitting $1.39. The stock had a trading volume of 220,254 shares, compared to its average volume of 602,451. The company’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.01. Myomo has a fifty-two week low of $0.60 and a fifty-two week high of $1.89. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The company has a market capitalization of $54.86 million, a P/E ratio of -4.04 and a beta of 1.50.

Myomo (NYSEAMERICAN:MYO) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. The business had revenue of $11.70 million for the quarter, compared to analyst estimates of $10.35 million. As a group, equities research analysts predict that Myomo will post -0.32 EPS for the current fiscal year.

Myomo News Summary

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Ascendiant Capital Markets maintained a Buy rating and a $10 price target, while raising its FY2026 EPS forecast to a loss of $0.32 from $0.34 and its FY2027 forecast to a loss of $0.22 from $0.25. The firm also improved its estimates for Q3 2026 and Q1 through Q3 2027, suggesting expectations for a gradual improvement in Myomo’s profitability. Ascendiant Capital Markets estimates for Myomo
• Positive Sentiment: Myomo announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference. The event could give management an opportunity to discuss demand for its wearable medical devices, growth plans and progress toward profitability, although no new financial details were provided in the announcement. Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
• Neutral Sentiment: The analyst’s current full-year EPS forecast of a $0.33 loss is close to Ascendiant’s $0.32 estimate, indicating limited near-term earnings visibility despite the more optimistic longer-term outlook.
• Negative Sentiment: Ascendiant lowered its Q4 2026 EPS estimate to a $0.08 loss from a $0.06 loss and reduced its Q4 2027 estimate to a $0.04 loss from a $0.03 loss. These downward revisions reinforce that Myomo remains unprofitable and could temper investor enthusiasm.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lifted their price objective on Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo has an average rating of “Buy” and an average price target of $10.00.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.